



Alaska Medical Assistance DUR Committee Meeting  
Friday, September 25, 2015  
1:00pm  
1.800.315.6338, access code 24251#

## Agenda

- (1) Review of minutes from the last meeting
- (2) Review of agenda
- (3) Comments/Suggestions from Committee members
- (4) Prospective Drug Utilization Review / Clinical Topic Areas:
  - a. New Prescription Medications (Interim PA List – 6 month review)
    - i. Benlysta, Zytiga, Zelboraf, Xalkori, Picato, Zioptan, Potiga, Xtandi, Bosulif, Stivarga, Xeljanz, Ilevro, Eliquis, Cometriq, Gattex, Invokana, Afinitor Disperz, Mekinist, Tafinlar, Tivicay, Gilotrif, Valchlor gel, Triumeq, Sutent, Isentress, Northera, Purixan, Cosentyx
  - b. Review of existing Prior Authorizations, Quantity Limits, Edits
    - i. FDA Indication Changes
    - ii. FDA Label Changes
    - iii. Periodic Review
      1. Hepatitis C, Direct Acting Agents
    - iv. Proposed New Prior Authorizations, Quantity Limits, Edits
      1. On-Label Prior Authorization utilizing ICD-10
- <<Break>>
- (5) Past Intervention Informational Updates
- (6) FDA/DEA Updates
  - a. FDA Drug Safety Communications
    - i. DPP-4 Inhibitors [8/28/2015]
    - ii. Picato [8/21/2015]
    - iii. Gilenya [8/4/2015]
    - iv. Brintellix, Brilinta [7/30/2015]
    - v. Potiga [6/16/2015]
    - vi. SGLT2 Inhibitors [5/15/2015]
- (7) FAERS Report
- (8) Quality Measures
- (9) Retrospective Review
  - a. Extended-release opioids
- (10) Standing Reviews
- (11) End of Public Meeting